244 related articles for article (PubMed ID: 21303732)
41. Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder.
Biederman J; Mick EO; Surman C; Doyle R; Hammerness P; Michel E; Martin J; Spencer TJ
BMC Psychiatry; 2007 Sep; 7():49. PubMed ID: 17868455
[TBL] [Abstract][Full Text] [Related]
42. Correlation of symptomatic improvements with functional improvements and patient-reported outcomes in adults with attention-deficit/hyperactivity disorder treated with OROS methylphenidate.
Rösler M; Ginsberg Y; Arngrim T; Adamou M; Niemelä A; Dejonkheere J; van Oene J; Schäuble B
World J Biol Psychiatry; 2013 May; 14(4):282-90. PubMed ID: 21517701
[TBL] [Abstract][Full Text] [Related]
43. The neuropsychological effects of chronic methylphenidate on drug-naive boys with attention-deficit/hyperactivity disorder.
Coghill DR; Rhodes SM; Matthews K
Biol Psychiatry; 2007 Nov; 62(9):954-62. PubMed ID: 17543895
[TBL] [Abstract][Full Text] [Related]
44. Does placebo response differ between objective and subjective measures in children with attention-deficit/hyperactivity disorder?
Sumner CR; Haynes VS; Teicher MH; Newcorn JH
Postgrad Med; 2010 Sep; 122(5):52-61. PubMed ID: 20861588
[TBL] [Abstract][Full Text] [Related]
45. Time course of treatment effect of OROS® methylphenidate in children with ADHD.
Armstrong RB; Damaraju CV; Ascher S; Schwarzman L; O'Neill J; Starr HL
J Atten Disord; 2012 Nov; 16(8):697-705. PubMed ID: 22084448
[TBL] [Abstract][Full Text] [Related]
46. Treatment of children with attention-deficit/hyperactivity disorder: results of a randomized, multicenter, double-blind, crossover study of extended-release dexmethylphenidate and D,L-methylphenidate and placebo in a laboratory classroom setting.
Silva R; Muniz R; McCague K; Childress A; Brams M; Mao A
Psychopharmacol Bull; 2008; 41(1):19-33. PubMed ID: 18362868
[TBL] [Abstract][Full Text] [Related]
47. Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidate.
Buitelaar JK; Casas M; Philipsen A; Kooij JJ; Ramos-Quiroga JA; Dejonckheere J; van Oene JC; Schäuble B
Psychol Med; 2012 Jan; 42(1):195-204. PubMed ID: 21733214
[TBL] [Abstract][Full Text] [Related]
48. [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)].
Golubchik P; Sever J; Weizman A
Harefuah; 2011 Oct; 150(10):788-90, 814. PubMed ID: 22111124
[TBL] [Abstract][Full Text] [Related]
49. Functional magnetic resonance imaging of methylphenidate and placebo in attention-deficit/hyperactivity disorder during the multi-source interference task.
Bush G; Spencer TJ; Holmes J; Shin LM; Valera EM; Seidman LJ; Makris N; Surman C; Aleardi M; Mick E; Biederman J
Arch Gen Psychiatry; 2008 Jan; 65(1):102-14. PubMed ID: 18180434
[TBL] [Abstract][Full Text] [Related]
50. Long-term effectiveness and safety of dexmethylphenidate extended-release capsules in adult ADHD.
Adler LA; Spencer T; McGough JJ; Jiang H; Muniz R
J Atten Disord; 2009 Mar; 12(5):449-59. PubMed ID: 19218542
[TBL] [Abstract][Full Text] [Related]
51. Academic, behavioral, and cognitive effects of OROS® methylphenidate on older children with attention-deficit/hyperactivity disorder.
Wigal SB; Wigal T; Schuck S; Brams M; Williamson D; Armstrong RB; Starr HL
J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):121-31. PubMed ID: 21488750
[TBL] [Abstract][Full Text] [Related]
52. Efficacy of two long-acting methylphenidate formulations in children with attention- deficit/hyperactivity disorder in a laboratory classroom setting.
Silva R; Muniz R; Pestreich LK; Brams M; Childress A; Lopez FA
J Child Adolesc Psychopharmacol; 2005 Aug; 15(4):637-54. PubMed ID: 16190795
[TBL] [Abstract][Full Text] [Related]
53. Improvements in executive function correlate with enhanced performance and functioning and health-related quality of life: evidence from 2 large, double-blind, randomized, placebo-controlled trials in ADHD.
Brown TE; Landgraf JM
Postgrad Med; 2010 Sep; 122(5):42-51. PubMed ID: 20861587
[TBL] [Abstract][Full Text] [Related]
54. Actigraphic monitoring during sleep of children with ADHD on methylphenidate and placebo.
Schwartz G; Amor LB; Grizenko N; Lageix P; Baron C; Boivin DB; Joober R
J Am Acad Child Adolesc Psychiatry; 2004 Oct; 43(10):1276-82. PubMed ID: 15381895
[TBL] [Abstract][Full Text] [Related]
55. Impact of methylphenidate delivery profiles on driving performance of adolescents with attention-deficit/hyperactivity disorder: a pilot study.
Cox DJ; Merkel RL; Penberthy JK; Kovatchev B; Hankin CS
J Am Acad Child Adolesc Psychiatry; 2004 Mar; 43(3):269-75. PubMed ID: 15076259
[TBL] [Abstract][Full Text] [Related]
56. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
Patkar AA; Masand PS; Pae CU; Peindl K; Hooper-Wood C; Mannelli P; Ciccone P
J Clin Psychopharmacol; 2006 Dec; 26(6):653-6. PubMed ID: 17110825
[TBL] [Abstract][Full Text] [Related]
57. Efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder.
Lee SI; Hong SD; Kim SY; Kim EJ; Kim JH; Kim JH; Park MK; Park S; Park JH; Oh EY; Lim TS; Cheong S; Cho IH; Choi JW
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):210-6. PubMed ID: 17046131
[TBL] [Abstract][Full Text] [Related]
58. OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder.
Ramos-Quiroga JA; Corominas M; Castells X; Bosch R; Casas M
Expert Rev Neurother; 2009 Aug; 9(8):1121-31. PubMed ID: 19673602
[TBL] [Abstract][Full Text] [Related]
59. A pilot study: differential effects of methylphenidate-OROS on working memory and attention functions in children with attention-deficit/hyperactivity disorder with and without behavioural comorbidities.
Rubio B; Hernández S; Verche E; Martín R; González-Pérez P
Atten Defic Hyperact Disord; 2011 Mar; 3(1):13-20. PubMed ID: 21432614
[TBL] [Abstract][Full Text] [Related]
60. Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data.
Sonuga-Barke EJ; Swanson JM; Coghill D; DeCory HH; Hatch SJ
BMC Psychiatry; 2004 Sep; 4():28. PubMed ID: 15458569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
